Edition:
India

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

78.73USD
2:05am IST
Change (% chg)

$1.54 (+2.00%)
Prev Close
$77.19
Open
$77.64
Day's High
$78.84
Day's Low
$77.64
Volume
919,368
Avg. Vol
1,144,399
52-wk High
$89.07
52-wk Low
$73.70

Select another date:

Wed, Feb 21 2018

Photo

Novo Nordisk gets nod from U.S. drug purchaser for new diabetes hope

COPENHAGEN Insulin maker Novo Nordisk said its Ozempic diabetes drug had been included on a list of medicines approved for patients covered by U.S. private health schemes, setting the stage for a battle with Eli Lilly's Trulicity.

Novo Nordisk gets nod from U.S. drug purchaser for new diabetes hope

COPENHAGEN, Feb 21 Insulin maker Novo Nordisk said its Ozempic diabetes drug had been included on a list of medicines approved for patients covered by U.S. private health schemes, setting the stage for a battle with Eli Lilly's Trulicity.

BRIEF-Adocia Files Additional Arbitration Claims Against Eli Lilly & Company​

* ‍ADOCIA FILES ADDITIONAL ARBITRATION CLAIMS AGAINST ELI LILLY & COMPANY​

BRIEF-Eli Lilly plans to deploy around $9 bln of global cash

* SEES 2018 EFFECTIVE TAX RATE OF 18%, DOWN FROM PREVIOUS NON-GAAP EXPECTATION OF 21.5%

BRIEF-NSAV Subsidiary Signs Agreement With Eli Lilly

* NSAV SUBSIDIARY SIGNS MAJOR AGREEMENT WITH ELI LILLY AND COMPANY

Lilly forecasts 2018 profit largely above estimates

Dec 13 Eli Lilly and Co on Wednesday forecast 2018 earnings largely above analysts' estimates in part due to strong demand for recently launched products such as diabetes drug Trulicity and psoriasis drug Taltz.

BRIEF-FDA Accepts Biologics License Application (BLA) To Review Galcanezumab For The Prevention Of Migraine In Adults

* FDA ACCEPTS BIOLOGICS LICENSE APPLICATION (BLA) TO REVIEW GALCANEZUMAB FOR THE PREVENTION OF MIGRAINE IN ADULTS

BRIEF-Novo Nordisk expects to launch new diabetes drug in Japan during H1 2018

Dec 6 NOVO NORDISK A/S CHIEF SCIENTIFIC OFFICER MADS KROGSGAARD THOMSEN MADE FOLLOWING COMMENTS DURING AN INVESTOR CALL FOLLOWING U.S. APPROVAL OF DIABETES DRUG OZEMPIC:

FDA approves Novo Nordisk diabetes drug Ozempic

The U.S. Food and Drug Administration on Tuesday approved Novo Nordisk A/S's diabetes drug Ozempic, setting the stage for a heated battle with Eli Lilly & Co's Trulicity.

UPDATE 3-U.S. FDA approves Novo Nordisk diabetes drug Ozempic

Dec 5 The U.S. Food and Drug Administration on Tuesday approved Novo Nordisk A/S's diabetes drug Ozempic, setting the stage for a heated battle with Eli Lilly & Co's Trulicity.

Select another date: